Christopher Byrne

Title: Christopher Byrne: Innovator in Cancer Research

Introduction

Christopher Byrne is a notable inventor based in Lifford, Ireland. He has made significant contributions to the field of cancer research, particularly in the development of assay methods that can aid in the treatment of breast cancer. His work focuses on the expression level of FKBPL, a marker that plays a crucial role in determining a subject's sensitivity to endocrine therapies.

Latest Patents

Christopher Byrne holds a patent for "Assay methods for the determination of FKBPL expression level in the context of breast cancer." This patent outlines methods that utilize FKBPL as a marker for assessing a patient's sensitivity to endocrine therapies in cancer treatment. It also serves as a predictive marker for cancer progression and disease-free survival in hormone-responsive cancers. He has 1 patent to his name.

Career Highlights

Byrne is affiliated with The Queen's University of Belfast, where he continues to advance his research in cancer therapies. His work has the potential to significantly impact the way breast cancer is treated, providing new avenues for patient care and management.

Collaborations

He collaborates with esteemed colleagues such as Tracy Robson and David Hirst, contributing to a dynamic research environment focused on innovative cancer treatments.

Conclusion

Christopher Byrne's contributions to cancer research through his innovative patent and collaborative efforts highlight his commitment to improving patient outcomes in breast cancer treatment. His work exemplifies the importance of research and innovation in the medical field.